$\require{mediawiki-texvc}$

연합인증

연합인증 가입 기관의 연구자들은 소속기관의 인증정보(ID와 암호)를 이용해 다른 대학, 연구기관, 서비스 공급자의 다양한 온라인 자원과 연구 데이터를 이용할 수 있습니다.

이는 여행자가 자국에서 발행 받은 여권으로 세계 각국을 자유롭게 여행할 수 있는 것과 같습니다.

연합인증으로 이용이 가능한 서비스는 NTIS, DataON, Edison, Kafe, Webinar 등이 있습니다.

한번의 인증절차만으로 연합인증 가입 서비스에 추가 로그인 없이 이용이 가능합니다.

다만, 연합인증을 위해서는 최초 1회만 인증 절차가 필요합니다. (회원이 아닐 경우 회원 가입이 필요합니다.)

연합인증 절차는 다음과 같습니다.

최초이용시에는
ScienceON에 로그인 → 연합인증 서비스 접속 → 로그인 (본인 확인 또는 회원가입) → 서비스 이용

그 이후에는
ScienceON 로그인 → 연합인증 서비스 접속 → 서비스 이용

연합인증을 활용하시면 KISTI가 제공하는 다양한 서비스를 편리하게 이용하실 수 있습니다.

[해외논문] Nitric oxide and postangioplasty restenosis: pathological correlates and therapeutic potential

Free radical biology & medicine, v.29 no.12, 2000년, pp.1199 - 1221  

Janero, David R (NitroMed, Inc., Bedford, MA, USA) ,  Ewing, James F (ArQule, Inc., Woburn, MA, USA)

Abstract AI-Helper 아이콘AI-Helper

AbstractBalloon angioplasty revolutionized interventional cardiology as a nonsurgical procedure to clear a diseased artery of atherosclerotic blockage. Despite its procedural reliability, angioplasty’s long-term outcome can be compromised by restenosis, the recurrence of arterial blockage in ...

주제어

참고문헌 (260)

  1. Circulation Pearson 97 602 1998 10.1161/01.CIR.97.6.602 Cardiovascular specialty societies and the emerging burden of cardiovascular disease. A call to action 

  2. Circulation Grundy 100 988 1999 10.1161/01.CIR.100.9.988 Primary prevention of coronary heart disease. Integrating risk assessment with intervention 

  3. N. Engl. J. Med. Gruentzig 301 61 1979 10.1056/NEJM197907123010201 Non-operative dilation of coronary artery stenosis 

  4. N. Engl. J. Med. King 331 1044 1994 10.1056/NEJM199410203311602 A randomized trial comparing coronary angioplasty with coronary bypass surgery 

  5. Circulation Hollman 68 725 1983 10.1161/01.CIR.68.4.725 Acute occlusion after percutaneous transluminal coronary angioplasty-new approach 

  6. N. Engl. J. Med. Ross 295 369 1976 10.1056/NEJM197608122950707 The pathogenesis of atherosclerosis 

  7. Fuster 1996 Atherosclerosis and coronary artery disease 

  8. Free Radic. Biol. Med. Janero 11 129 1991 10.1016/0891-5849(91)90193-7 Therapeutic potential of vitamin E in the pathogenesis of spontaneous atherosclerosis 

  9. Clin. Cardiol. Vogel 20 426 1997 10.1002/clc.4960200505 Coronary risk factors, endothelial function, and atherosclerosis 

  10. Cardiovasc. Drugs Ther. Opie 4 777 1990 10.1007/BF00051275 Myocardial ischemia-metabolic pathways and implications of increased glycolysis 

  11. Crit. Rev. Food Sci. Nutr. Janero 35 65 1995 10.1080/10408399509527688 Ischemic heart disease and antioxidants 

  12. Janero 411 1994 Natural antioxidants in human health and disease Myocardial ischemia-reperfusion injury and the cardioprotective potential of natural antioxidants 

  13. 10.1161/01.CIR.100.1.14 Berger, P. B.; Ellis, S. G.; Holmes, D. R.; Granger, C. G.; Criger, D. A.; Betriu, A.; Topol, E. J.; Califf, R. M., for the GUSTO-II investigators. Relationship between delay in performing direct coronary angioplasty and early clinical outcome in patients with acute myocardial infarction. Results from the global use of strategies to open occluded arteries in acute coronary syndromes (GUSTO-IIb) trial. Circulation 100:14-20; 1999. 

  14. Circulation Kaiser 72 V-46 1985 CABG 1984 

  15. Eur. Heart J. Yusuf 6 556 1985 10.1093/oxfordjournals.eurheartj.a061905 Intravenous and intracoronary fibrinolytic therapy in acute myocardial infarction 

  16. Circulation White 97 1632 1998 10.1161/01.CIR.97.16.1632 Thrombolysis for acute myocardial infarction 

  17. Circulation Ellis 81 IV-43 1990 Interventions in acute myocardial infarction 

  18. Am. J. Cardiol. Weintraub 65 183 1990 10.1016/0002-9149(90)90082-C Changing use of coronary angioplasty and coronary bypass surgery in the treatment of chronic coronary artery disease 

  19. Ann. Thorac. Surg. Oesterle 66 1045 1998 10.1016/S0003-4975(98)00713-9 Beyond stents 

  20. Baim 1986 Cardiac catheterization and angiography Coronary angioplasty 

  21. Circulation Kornowski 97 1355 1998 10.1161/01.CIR.97.14.1355 Procedural results and late clinical outcomes after placement of three or more stents in single coronary lesions 

  22. J. Am. Med. Assoc. Weaver 278 2093 1997 10.1001/jama.278.23.2093 Comparison of primary coronary angioplasty and intravenous thrombolytic therapy for acute myocardial infarction 

  23. Prog. Cardiovasc. Dis. Bauters 40 107 1997 10.1016/S0033-0620(97)80003-5 The biology of restenosis 

  24. Cardiol. Rev. Casterella 7 219 1999 10.1097/00045415-199907000-00014 Prevention of coronary restenosis 

  25. Hum. Pathol. Waller 18 476 1987 10.1016/S0046-8177(87)80032-1 Pathology of transluminal balloon angioplasty used in the treatment of coronary heart disease 

  26. Am. J. Cardiol. Bertrand 63 277 1989 10.1016/0002-9149(89)90330-5 Relation to restenosis after percutaneous transluminal coronary angioplasty to vasomotion of the dilated coronary arterial segment 

  27. Hum. Pathol. Gravanis 20 477 1989 10.1016/0046-8177(89)90014-2 Histopathologic phenomena at the site of percutaneous transluminal coronary angioplasty 

  28. Am. J. Cardiol. Potkin 62 41 1998 10.1016/0002-9149(88)91362-8 Effects of coronary angioplasty on atherosclerotic plaques and relation of plaque composition and arterial size to outcome 

  29. Circulation Serruys 77 361 1988 10.1161/01.CIR.77.2.361 Incidence of restenosis after successful coronary angioplasty 

  30. Cardiol. Rev. Fleisch 7 215 1999 10.1097/00045415-199907000-00013 Management and outcome of stents in 1998 

  31. Prog. Cardiovasc. Dis. Lefkovits 40 141 1997 10.1016/S0033-0620(97)80006-0 Pharmacological approaches for the prevention of restenosis after percutaneous coronary intervention 

  32. Circulation Liu 79 1374 1989 10.1161/01.CIR.79.6.1374 Restenosis after coronary angioplasty. Potential biologic determinants and role of intimal hyperplasia 

  33. Cardiovasc. Pathol. Anderson 1 263 1992 10.1016/1054-8807(92)90037-O Restenosis 

  34. Circ. Res. Lafont 76 996 1995 10.1161/01.RES.76.6.996 Restenosis after experimental angioplasty 

  35. Cardiovasc. Res. Bauters 31 835 1996 10.1016/S0008-6363(96)00038-7 Mechanisms and prevention of restenosis 

  36. Circulation Mintz 94 35 1996 10.1161/01.CIR.94.1.35 Arterial remodeling after coronary angioplasty 

  37. Ann. N. Y. Acad. Sci. Mak 811 255 1997 10.1111/j.1749-6632.1997.tb52007.x Clinical trials to prevent restenosis after percutaneous coronary revascularization 

  38. Circulation Gallo 97 581 1998 10.1161/01.CIR.97.6.581 Prolonged thrombin inhibition reduces restenosis after balloon angioplasty in porcine coronary arteries 

  39. Cardiovasc. Res. Lafont 39 50 1998 10.1016/S0008-6363(98)00109-6 Why do animal models of post-angioplasty restenosis sometimes poorly predict the outcome of clinical trials? 

  40. Am. J. Cardiol. Di Mario 75 772 1995 10.1016/S0002-9149(99)80409-3 Quantitative assessment with intracoronary ultrasound of the mechanisms of restenosis after percutaneous transluminal coronary angioplasty and directional coronary atherectomy 

  41. Circulation Post 96 996 1997 10.1161/01.CIR.96.3.996 Arterial remodeling after balloon angioplasty or stenting in an atherosclerotic experimental model 

  42. J. Am. Coll. Cardiol. Chandrasekar 35 555 2000 10.1016/S0735-1097(99)00596-3 Platelets and restenosis 

  43. Circulation Ruygrok 94 882 1996 10.1161/01.CIR.94.5.882 Intracoronary stenting. From concept to custom 

  44. Circulation Hoffmann 94 1247 1996 10.1161/01.CIR.94.6.1247 Patterns and mechanisms of in-stent restenosis 

  45. Circulation Komatsu 98 224 1998 10.1161/01.CIR.98.3.224 Neointimal tissue response at sites of coronary stenting in humans. Macroscopic, histological, and immunohistochemical analyses 

  46. Circulation Carrozza 100 756 1999 10.1161/01.CIR.100.7.756 In vivo assessment of stent expansion and recoil in normal porcine coronary arteries. Differential outcome by stent design 

  47. Circ. Res. Rogers 84 378 1999 10.1161/01.RES.84.4.378 Balloon-artery interactions during stent placement. A finite element analysis approach to pressure, compliance, and stent design as contributors to vascular injury 

  48. N. Engl. J. Med. Kimura 334 561 1996 10.1056/NEJM199602293340903 Three-year follow-up after implantation of metallic coronary-artery stents 

  49. 10.1016/0735-1097(95)00473-4 Macaya, C.; Serruys, P. W.; Ruygrok, P.; Suryapranata, H.; Mast, G.; Klugmann, S.; Urban, P.; den Heijer, P.; Koch, K.; Simon, R.; Morice, M. C.; Crean, P.; Bonnier, H.; Wijns, W.; Danchin, N.; Bourdonnec, C.; Morel, M. A., for the Benestent Study Group. Continued benefit for coronary stenting compared to balloon angioplasty: one year clinical follow-up of the Benestent trial. J. Am. Coll. Cardiol. 27:255-261; 1996. 

  50. Circulation Asakura 97 2003 1998 10.1161/01.CIR.97.20.2003 Remodeling of in-stent neointima, which became thinner and transparent over 3 years. Serial angiographic and angioscopic follow-up 

  51. J. Am. Coll. Cardiol. Reimers 30 186 1997 10.1016/S0735-1097(97)00142-3 Long-term clinical follow-up after successful repeat percutaneous intervention for in-stent restenosis 

  52. Circulation Bauters 97 318 1998 10.1161/01.CIR.97.4.318 Six-month angiographic outcome after successful repeat percutaneous intervention for in-stent restenosis 

  53. Pathol. Int. Yutani 49 273 1999 10.1046/j.1440-1827.1999.00861.x Coronary atherosclerosis and interventions 

  54. J. Am. Coll. Cardiol. Bertrand 32 562 1998 10.1016/S0735-1097(98)00289-7 Biocompatibility aspects of new stent technology 

  55. Thromb. Haemost. Rosanio 82 164 2000 Prevention of restenosis after percutaneous interventions 

  56. Circulation Edelman 100 896 1999 10.1161/01.CIR.100.9.896 Stent-versus-stent equivalency trials. Are some stents more equal than others? 

  57. Arch. Biochem. Biophys. Ewing 343 131 1997 10.1006/abbi.1997.0169 Reactivity of nitrogen monoxide species with NADH 

  58. J. Pharmacol. Exp. Ther. Ewing 283 947 1997 Nitrosylated bovine serum albumin derivatives as pharmacologically active nitric oxide congeners 

  59. Trends Biochem. Sci. Mayer 22 477 1997 10.1016/S0968-0004(97)01147-X Biosynthesis and action of nitric oxide in mammalian cells 

  60. Curr. Opin. Chem. Biol. Bohle 2 194 1998 10.1016/S1367-5931(98)80060-4 Pathophysiological chemistry of nitric oxide and its oxygenation by-products 

  61. Free Radic. Biol. Med. Ewing 25 621 1998 10.1016/S0891-5849(98)00083-5 Specific S-nitrosothiol (thionitrite) quantification as solution nitrite after vanadium(III) reduction and ozone-chemiluminescent detection 

  62. Free Radic. Biol. Med. Wink 25 434 1998 10.1016/S0891-5849(98)00092-6 Chemical biology of nitric oxide 

  63. Free Radic. Biol. Med. Janero 28 1495 2000 10.1016/S0891-5849(00)00247-1 Nitric oxide (NO)-related pharmaceuticals 

  64. Nature Furchgott 288 373 1980 10.1038/288373a0 The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine 

  65. Trends Pharmacol. Sci. Shulz 15 255 1994 10.1016/0165-6147(94)90321-2 Role of NO in vascular smooth muscle and cardiac muscle function 

  66. Curr. Opin. Chem. Biol. Marletta 2 656 1998 10.1016/S1367-5931(98)80098-7 Catalysis by nitric oxide synthase 

  67. Arteroscler. Thromb. Tarry 14 938 1994 10.1161/01.ATV.14.6.938 L-arginine improves endothelium-dependent vasorelaxation and reduces intimal hyperplasia after balloon angioplasty 

  68. J. Pharmacol. Exp. Ther. Martin 232 708 1985 Selective blockade of endothelium-dependent and glyceryl trinitrate-induced relaxation by hemoglobin and by methylene blue in the rabbit aorta 

  69. Hypertension Dubey 31 296 1998 10.1161/01.HYP.31.1.296 Cyclic AMP-adenosine pathway induces nitric oxide synthesis in aortic smooth muscle cells 

  70. Arterioscler. Thromb. Vasc. Biol. Dimmeler 19 656 1999 10.1161/01.ATV.19.3.656 Upregulation of superoxide dismutase and nitric oxide synthase mediates the apoptosis-suppressive effects of shear stress on endothelial cells 

  71. Am. J. Physiol. Ma 271 H2045 1996 Exogenous NO inhibits basal NO release from vascular endothelium in vitro and in vivo 

  72. J. Vasc. Res. Dusting 32 143 1995 10.1159/000159089 Nitric oxide in cardiovascular disorders 

  73. Lancet Petros 338 1557 1991 10.1016/0140-6736(91)92376-D Effect of nitric oxide synthase inhibitors on hypotension in patients with septic shock 

  74. J. Am. Coll. Cardiol. Williams 27 567 1996 10.1016/0735-1097(95)00522-6 Impaired nitric oxide-mediated vasodilation in patients with non-insulin-dependent diabetes mellitus 

  75. Vasc. Med. Cardillo 3 138 1998 10.1177/1358836X9800300208 Impaired endothelial regulation of vascular tone in patients with systemic arterial hypertension 

  76. Hypertension Gerhard 27 849 1996 10.1161/01.HYP.27.4.849 Aging progressively impairs endothelium-dependent vasodilation in forearm resistance vessels of humans 

  77. Circ. Res. Cernadas 83 279 1998 10.1161/01.RES.83.3.279 Expression of constitutive and inducible nitric oxide synthases in the vascular wall of young and aging rats 

  78. J. Vasc. Res. Sarkar 35 135 1998 10.1159/000025576 Does nitric oxide regulate smooth muscle cell proliferation? 

  79. Proc. Natl. Acad. Sci. USA Radomski 87 5193 1990 10.1073/pnas.87.13.5193 An L-arginine/nitric oxide pathway present in human platelets regulates aggregation 

  80. J. Clin. Invest. Zimmerman 98 1699 1996 10.1172/JCI118967 Adhesion and signaling in vascular cell-cell interactions 

  81. J. Clin. Invest. Freedman 100 350 1997 10.1172/JCI119540 Nitric oxide released from activated platelets inhibits platelet recruitment 

  82. Am. J. Physiol. Armstead 273 H740 1997 Regulation of P-selectin expression in human endothelial cells by nitric oxide 

  83. Lancet Celermajer 340 1111 1992 10.1016/0140-6736(92)93147-F Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis 

  84. Circulation Oemar 97 2494 1998 10.1161/01.CIR.97.25.2494 Reduced endothelial nitric oxide synthase expression and production in human atherosclerosis 

  85. J. Cardiovasc. Pharmacol. Freeman 28 345 1996 10.1097/00005344-199609000-00001 Analysis of lysophosphatidylcholine-induced endothelial dysfunction 

  86. Circulation Bauersachs 100 292 1999 10.1161/01.CIR.100.3.292 Endothelial dysfunction in chronic myocardial infarction despite increased vascular endothelial nitric oxide synthase and soluble guanylate cyclase expression. Role of enhanced vascular superoxide production 

  87. Circulation Ito 99 3092 1999 10.1161/01.CIR.99.24.3092 Novel mechanism for endothelial dysfunction. Dysregulation of dimethyl arginine dimethylaminohydrolase 

  88. J. Biol. Chem. Liao 270 319 1995 10.1074/jbc.270.1.319 Oxidized low density lipoprotein decreases the expression of endothelial nitric oxide synthase 

  89. Circulation John 98 211 1998 10.1161/01.CIR.98.3.211 Increased bioavailability of nitric oxide after lipid-lowering therapy in hypercholesterolemic patients. A randomized, placebo-controlled, double-blind study 

  90. N. Engl. J. Med. DeWood 303 897 1980 10.1056/NEJM198010163031601 Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction 

  91. J. Clin. Invest. Freedman 97 979 1996 10.1172/JCI118522 Decreased platelet inhibition by nitric oxide in two brothers with a history of arterial thrombosis 

  92. J. Clin. Invest. Cooke 90 1168 1992 10.1172/JCI115937 Antiatherogenic effects of L-arginine in the hypercholesterolemic rabbit 

  93. Circulation Lerman 97 2123 1998 10.1161/01.CIR.97.21.2123 Long-term L-arginine supplementation improves small-vessel coronary endothelial function in humans 

  94. Arterioscler. Thromb. Vasc. Biol. Naruse 14 746 1992 10.1161/01.ATV.14.5.746 Long-term inhibition of NO synthesis promotes atherosclerosis in the hypercholesterolemic rabbit thoracic aorta 

  95. Annu. Rev. Med. Lloyd-Jones 47 365 1996 10.1146/annurev.med.47.1.365 The vascular biology of nitric oxide and its role in atherogenesis 

  96. Am. J. Pathol. O’Brien 145 883 1994 Angiogenesis in human coronary atherosclerotic plaques 

  97. Surgery Sarkar 118 274 1995 10.1016/S0039-6060(05)80334-4 Nitric oxide inhibition of endothelial cell mitogenesis and proliferation 

  98. Circulation Yao 86 1302 1992 10.1161/01.CIR.86.4.1302 Endogenous nitric oxide protects against platelet aggregation and cyclic flow variations in stenosed and endothelium-injured arteries 

  99. Circ. Res. Niu 74 1133 1994 10.1161/01.RES.74.6.1133 Intracellular oxidative stress induced by nitric oxide synthesis inhibition increases endothelial cell adhesion to neutrophils 

  100. Circulation Waller 83 I-28 1991 Morphological observations late (greater than 30 days) after clinically successful coronary balloon angioplasty 

  101. Circ. Res. Shimokawa 65 740 1989 10.1161/01.RES.65.3.740 Natural course of the impairment of endothelium-dependent relaxations after balloon endothelium removal in porcine coronary arteries 

  102. Circulation Van Belle 95 438 1997 10.1161/01.CIR.95.2.438 Stent endothelialization 

  103. Eur. J. Pharmacol. Bosmans 310 163 1996 10.1016/0014-2999(96)00377-9 Balloon angioplasty and induction of non-endothelial nitric oxide synthase in rabbit carotid arteries 

  104. Circ. Res. Yan 82 21 1998 10.1161/01.RES.82.1.21 Overexpression of inducible nitric oxide synthase by neointimal smooth muscle cells 

  105. Gen. Pharmacol. Hecker 32 9 1999 10.1016/S0306-3623(98)00082-2 Regulation of inducible nitric oxide synthase gene expression in vascular smooth muscle cells 

  106. Eur. J. Pharmacol. Douglas 255 81 1994 10.1016/0014-2999(94)90085-X Functional evidence that balloon angioplasty results in transient nitric oxide synthase induction 

  107. Pediatr. Clin. North Am. Nelin 45 531 1998 10.1016/S0031-3955(05)70026-2 The use of inhaled nitric oxide in a wide variety of clinical problems 

  108. Circ. Res. Lee 78 337 1996 10.1161/01.RES.78.2.337 Chronic inhalation of nitric oxide inhibits neointimal formation after balloon-induced arterial injury 

  109. Circulation Adrie 94 1919 1996 10.1161/01.CIR.94.8.1919 Inhaled nitric oxide increases coronary artery patency after thrombolysis 

  110. Circ. Res. Kelm 66 1561 1990 10.1161/01.RES.66.6.1561 Control of coronary vascular tone by nitric oxide 

  111. Arch. Environ. Health Hugod 34 12 1979 10.1080/00039896.1979.10667360 Ultrastructural changes of the rabbit lung after 5 ppm nitric oxide exposure 

  112. Environ. Res. Kagawa 22 485 1982 10.1016/0013-9351(82)90103-7 Respiratory effects of 2-hr exposure to 1.0 ppm nitric oxide in normal subjects 

  113. Circ. Res. Girerd 67 1301 1990 10.1161/01.RES.67.6.1301 L-arginine augments endothelium-dependent vasodilation in cholesterol rabbits 

  114. Circulation Cooke 83 1057 1991 10.1161/01.CIR.83.3.1057 Arginine restores cholinergic relaxation of hypercholesterolemic rabbit thoracic aorta 

  115. J. Clin. Invest. Rossitch 87 1295 1991 10.1172/JCI115132 L-arginine normalizes endothelial function in cerebral vessels from hypercholesterolemic rabbits 

  116. Atherosclerosis Boger 136 67 1998 10.1016/S0021-9150(97)00183-4 Dietary L-arginine decreases myointimal cell proliferation and vascular monocyte accumulation in cholesterol-fed rabbits 

  117. J. Cardiovasc. Pharmacol. Singer 25 710 1995 10.1097/00005344-199505000-00005 Discordant effects of dietary L-arginine on vascular structure and reactivity in hypercholesterolemic rabbits 

  118. Lancet Drexler 338 1546 1991 10.1016/0140-6736(91)92372-9 Correction of endothelial dysfunction in coronary microcirculation of hypercholesterolemic patients by L-arginine 

  119. Am. J. Cardiol. Dubois-Rande 70 1269 1992 10.1016/0002-9149(92)90760-V Effects of infusion of L-arginine into the left anterior descending coronary artery on acetylcholine-induced vasoconstriction of human atheromatous coronary arteries 

  120. J. Cardiovasc. Pharmacol. Chin-Dusting 28 158 1996 10.1097/00005344-199607000-00023 Effects of in vivo and in vitro L-arginine supplementation on healthy human vessels 

  121. J. Clin. Invest. Wang 23 452 1994 Dietary arginine prevents atherogenesis in the coronary artery of the hypercholesterolemic rabbit 

  122. Arterioscler. Thromb. Vasc. Biol. Candipan 16 44 1996 10.1161/01.ATV.16.1.44 Regression or progression. Dependency on vascular nitric oxide 

  123. Circulation Boger 96 1282 1997 10.1161/01.CIR.96.4.1282 Dietary L-arginine reduces the progression of atherosclerosis in cholesterol-fed rabbits. Comparison with lovastatin 

  124. Circulation Aji 95 430 1997 10.1161/01.CIR.95.2.430 L-arginine prevents xanthoma development and inhibits atherosclerosis in LDL cholesterol receptor knockout mice 

  125. Biochem. Biophys. Res. Commun. McNamara 193 291 1993 10.1006/bbrc.1993.1622 L-arginine inhibits balloon catheter-induced intimal hyperplasia 

  126. Life Sci. Taguchi 53 387 1993 10.1016/0024-3205(93)90167-2 L-arginine inhibits neointimal formation following balloon injury 

  127. Circulation Hamon 90 1357 1994 10.1161/01.CIR.90.3.1357 Long-term administration of L-arginine reduces intimal thickening and enhances neoendothelium-dependent acetylcholine-induced relaxation after arterial injury 

  128. Chin. Med. J. Zhijian 109 592 1996 Long-term oral administration of L-arginine enhances endothelium-dependent vasorelaxation and inhibits neointimal thickening after endothelial denudation in rats 

  129. Arterioscler. Thromb. Vasc. Biol. Bosmans 19 767 1999 10.1161/01.ATV.19.3.767 Continuous perivascular L-arginine delivery increases total vessel area and reduces neointimal thickening after experimental balloon dilatation 

  130. J. Am. Coll. Cardiol. Wang 28 1573 1996 10.1016/S0735-1097(96)00337-3 Arginine restores nitric oxide activity and inhibits monocyte accumulation after vascular injury in hypercholesterolemic rabbits 

  131. J. Am. Coll. Cardiol. Le Tourneau 33 876 1999 10.1016/S0735-1097(98)00621-4 Role of nitric oxide in restenosis after experimental balloon angioplasty in the hypercholesterolemic rabbit 

  132. Circulation Schwarzacher 95 1863 1997 10.1161/01.CIR.95.7.1863 Local intramural delivery of L-arginine enhances nitric oxide generation and inhibits lesion formation after balloon angioplasty 

  133. Circulation Niebauer 100 1830 1999 10.1161/01.CIR.100.17.1830 Local L-arginine delivery after balloon angioplasty reduced monocyte binding and induces apoptosis 

  134. Cardiovasc. Res. Greenlees 35 351 1997 10.1016/S0008-6363(97)00122-3 The effects of L-arginine on neointimal formation and vascular function following balloon injury in heritable hyperlipidemic rabbits 

  135. N. Engl. J. Med. Adelman 329 221 1993 10.1056/NEJM199307223290401 A comparison of directional atherectomy with coronary angioplasty in patients with coronary artery disease. The CAVEAT Study Group 

  136. J. Clin. Invest. Giugliano 99 433 1997 10.1172/JCI119177 The vascular effects of L-arginine in humans 

  137. Circulation Cardillo 100 820 1999 10.1161/01.CIR.100.8.820 Insulin stimulates both endothelium and nitric oxide activity in the human forearm 

  138. J. Clin. Invest. Ohara 91 2546 1993 10.1172/JCI116491 Hypercholesterolemia increases endothelial superoxide anion production 

  139. Biochemistry Sennequier 35 5883 1996 10.1021/bi952844e Analysis of substrate-induced electronic, catalytic, and structural changes in inducible NO synthase 

  140. Circ. Res. Durante 78 1075 1996 10.1161/01.RES.78.6.1075 Differential regulation of L-arginine transport and nitric oxide production by vascular smooth muscle and endothelium 

  141. J. Am. Coll. Cardiol. Quyyumi 32 904 1998 10.1016/S0735-1097(98)00323-4 Does acute improvement of endothelial dysfunction in coronary artery disease improve myocardial ischemia? A double-blind comparison of parenteral D- and L-arginine 

  142. Hypertension Hattori 33 943 1999 10.1161/01.HYP.33.4.943 Troglitazone upregulates nitric oxide synthesis in vascular smooth muscle cells 

  143. FEBS Lett. Hishikawa 360 291 1995 10.1016/0014-5793(95)00124-R Up-regulation of nitric oxide synthase by estradiol in human aortic endothelial cells 

  144. J. Clin. Invest. DiMinno 75 328 1985 10.1172/JCI111705 Functionally thrombasthenic state in normal platelets following administration of ticlopidine 

  145. Hypertension Frolich 13 I-1125 1989 Angiotesin converting enzyme inhibitors 

  146. Allergol. Immunopathol. Garcia 18 53 1990 New approach to the mechanism of antiasthmatic action of tranilast 

  147. J. Cardiovasc. Pharmacol. Hishikawa 28 200 1996 10.1097/00005344-199608000-00004 Tranilast restores cytokine-induced nitric oxide production against platelet-derived growth factor in vascular smooth muscle cells 

  148. Eur. J. Pharmacol. Ikeda 314 197 1996 10.1016/S0014-2999(96)00551-1 Effect of cilostazol, a cAMP phosphodiesterase inhibitor, on nitric oxide production by vascular smooth muscle cells 

  149. Br. J. Pharmacol. Hecker 120 1067 1997 10.1038/sj.bjp.0701026 Induction by staurosporine of nitric oxide synthase expression in vascular smooth muscle cells 

  150. Circulation Ikeda 99 1230 1999 10.1161/01.CIR.99.9.1230 Homocysteine increases nitric oxide synthesis in cytokine-stimulated vascular smooth muscle cells 

  151. Cardiovasc. Res. Ikeda 35 168 1997 10.1016/S0008-6363(97)00068-0 Adenosine stimulates nitric oxide synthesis in vascular smooth muscle cells 

  152. Hypertension Inoue 25 711 1995 10.1161/01.HYP.25.4.711 cGMP upregulates nitric oxide synthase expression in vascular smooth muscle cells 

  153. Hypertension Oparil 33 II-170 1999 10.1161/01.HYP.33.1.170 Hormones and vasoprotection 

  154. J. Clin. Invest. Law 98 1897 1996 10.1172/JCI118991 Troglitazone inhibits vascular smooth muscle cell growth and intimal hyperplasia 

  155. J. Vasc. Surg. Foegh 19 722 1994 10.1016/S0741-5214(94)70047-8 Estradiol inhibition of arterial neointimal hyperplasia after balloon injury 

  156. Circulation Levine 94 2221 1996 10.1161/01.CIR.94.9.2221 Medroxyprogesterone attenuates estrogen-mediated inhibition of neointima formation after balloon injury of the rat carotid artery 

  157. J. Clin. Invest. Sullivan 96 2482 1995 10.1172/JCI118307 Estrogen inhibits the response-to-injury in a mouse carotid artery model 

  158. J. Am. Coll. Cardiol. Geary 31 1158 1998 10.1016/S0735-1097(98)00042-4 Conjugated equine estrogens inhibit progression of atherosclerosis but have no effect on intimal hyperplasia or arterial remodeling induced by balloon catheter injury in monkeys 

  159. Circulation Holm 100 1727 1999 10.1161/01.CIR.100.16.1727 The direct antiatherogenic effect of estrogen is present, absent, or reversed, depending on the state of the arterial endothelium. A time course study in cholesterol-clamped rabbits 

  160. J. Cardiovasc. Pharmacol. De Lorgeril 32 225 1998 10.1097/00005344-199808000-00009 Ticlopidine increases nitric oxide generation in heart-transplant recipients 

  161. Bertrand, M. E.; Allain, H.; LaBlanche, J. M., on behalf of the investigators of the TACT study. Results of a randomized trial of ticlopidine versus placebo for the prevention of acute closure and restenosis after coronary angioplasty (PTCA): the TACT study. Circulation 82:III-190 (abstr.); 1990. 

  162. White, C. W.; Knudson, M.; Schmidt, D.; Chisholm, R. J.; Vandormael, M.; Morton, B.; Roy, L.; Khaja, F.; Reitman, M., and the Ticlopidine Study Group. Neither ticlopidine or aspirin-dipyridamole prevents restenosis post-PTCA: results from a randomized placebo-controlled multicenter trial. Circulation 76:IV-213 (abstr.); 1997. 

  163. Kitazume, H.; Kubo, I.; Iwama, T.; Ageishi, Y.; Suzuki, A. Combined use of aspirin, ticlopidine and nicorandil prevented restenosis after coronary angioplasty. Circulation 78:II-633 (abstr.); 1998. 

  164. Science Powell 245 186 1989 10.1126/science.2526370 Inhibitors of angiotensin-converting enzyme prevent myointimal proliferation after vascular injury 

  165. Jpn. Circ. J. Miyauchi 62 53 1998 10.1253/jcj.62.53 Limitations of angiotensin-converting enzyme inhibitor in restenosis of a deep arterial injury model 

  166. Circulation 86 100 1994 Does the new angiotensin converting enzyme inhibitor cilazapril prevent restenosis after percutaneous transluminal coronary angioplasty? Results of the MERCATOR study 

  167. J. Am. Coll. Cardiol. Faxon 25 362 1995 10.1016/0735-1097(94)00368-Z Effect of high dose angiotensin-converting enzyme inhibition on restenosis 

  168. Circulation Desmet 89 385 1994 10.1161/01.CIR.89.1.385 Angiotensin-converting enzyme inhibition with fosinopril sodium in the prevention of restenosis after coronary angioplasty 

  169. Clin. Cardiol. Gibbons 20 II-18 1997 10.1002/j.1932-8737.1997.tb00008.x Vasculoprotective and cardioprotective mechanisms of angiotensin-converting enzyme inhibition 

  170. Hypertension Hanson 18 II-70 1991 10.1161/01.HYP.18.4_Suppl.II70 Effects of angiotensin converting enzyme inhibition with cilazapril on intimal hyperplasia in injured arteries and vascular grafts in baboon 

  171. J. Cardiovasc. Pharmacol. Miyazawa 30 157 1997 10.1097/00005344-199708000-00002 Effects of pemirolast and tranilast on intimal thickening after arterial injury in the rat 

  172. Eur. J. Pharmacol. Fukuyama 318 327 1996 10.1016/S0014-2999(96)00774-1 Tranilast suppresses the vascular intimal hyperplasia after balloon injury in rabbits fed on a high-cholesterol diet 

  173. Udea, K.; Tamai, H.; Hsu, Y.-S. Efficacy of tranilast on restenosis after percutaneous transluminal coronary angioplasty in small sized coronary arteries. Circulation 92:I-346; 1995. 

  174. 10.1016/0735-1097(95)92396-M Udea, K.; Tamai, H.; Hsu, Y.-S.; Ono, S.; Tanaka, S.; Kosuga, K.; Okada, M.; Wan, M.; Motohara, S.; Uehata, H. Efficacy of tranilast on restenosis after coronary angioplasty: is there any rebound phenomenon after ceasing tranilast at 3 months? J. Am. Coll. Cardiol. 25:225A (abstr.); 1995. 

  175. Udea, K.; Tamai, H.; Kyo, E. Efficacy of tranilast on restenosis after PTCA. Jpn. J. Interventional Cardiol. 8:104 (abstr.); 1993. 

  176. Am. Heart J. Kosuga 134 712 1997 10.1016/S0002-8703(97)70055-3 Effectiveness of tranilast on restenosis after directional coronary athrectomy 

  177. Am. Heart. J. Holmes 139 23 2000 10.1016/S0002-8703(00)90304-1 The PRESTO (prevention of restenosis with tranilast and its outcomes) protocol 

  178. Jpn. Circ. J. Tsutsui 60 207 1996 10.1253/jcj.60.207 Effect of cilostazol, a novel anti-platelet drug, on restenosis after percutaneous transluminal coronary angioplasty 

  179. Atherosclerosis Ishizaka 142 41 1999 10.1016/S0021-9150(98)00147-6 Effects of a single local administration of cilostazol on neointimal formation in balloon-injured rat carotid artery 

  180. Am. J. Cardiol. Take 79 1097 1997 10.1016/S0002-9149(97)00052-0 Effect of cilostazol in preventing restenosis after percutaneous transluminal coronary angioplasty 

  181. Circulation Tsuchikane 100 21 1999 10.1161/01.CIR.100.1.21 Impact of cilostazol on restenosis after percutaneous coronary balloon angioplasty 

  182. Am. Heart J. Tsuchikane 135 495 1998 10.1016/S0002-8703(98)70327-8 Impact of cilostazol on intimal proliferation after directional coronary atherectomy 

  183. Clin. Ther. Kunishima 19 1058 1997 10.1016/S0149-2918(97)80058-6 A randomized trial of aspirin versus cilostazol therapy after successful coronary stent implantation 

  184. Am. J. Cardiol. Sekiya 82 144 1998 10.1016/S0002-9149(98)00323-3 Effects of probucol and cilostazol alone or in combination on frequency of poststenting restenosis 

  185. Cathet. Cardiovasc. Diagn. Yamasaki 44 387 1998 10.1002/(SICI)1097-0304(199808)44:4<387::AID-CCD4>3.0.CO;2-0 Effects of cilostazol on late lumen loss after Palmaz-Schatz stent implantation 

  186. J. Vasc. Res. Busse 35 73 1998 10.1159/000025568 Pulsatile stretch and shear stress 

  187. Arterioscler. Thromb. Vasc. Biol. Lewis 19 2782 1999 10.1161/01.ATV.19.11.2782 Exercise training increases basal nitric oxide production from the forearm in hypercholesterolemic patients 

  188. Life Sci. Posch 64 663 1999 10.1016/S0024-3205(98)00608-0 Selective stimulation of L-arginine uptake contributes to shear stress-induced formation of nitric oxide 

  189. Jpn. Circ. J. Kubo 56 413 1992 10.1253/jcj.56.413 Preventive effect of exercise training on recurrent stenosis after percutaneous transluminal coronary angioplasty (PTCA) 

  190. Nature Med. Williams 3 273 1997 10.1038/nm0397-273 Estrogens, progestins and coronary artery reactivity 

  191. Eur. J. Pharmacol. Nishio 374 127 1999 10.1016/S0014-2999(99)00271-X Troglitazone inhibits alpha-1-adrenoreceptor-induced DNA synthesis in vascular smooth muscle cells 

  192. Am. J. Respir. Cell. Mol. Biol. Haddad 16 501 1997 10.1165/ajrcmb.16.5.9160832 Modulation of adenovirus-mediated gene transfer by nitric oxide 

  193. Curr. Opin. Nephrol. Hypertens. Kibbe 8 75 1999 10.1097/00041552-199901000-00012 Nitric oxide synthase gene transfer to the vessel wall 

  194. Molec. Med. Tzeng 2 211 1996 10.1007/BF03401618 Vascular gene transfer of the human inducible nitric oxide synthase 

  195. Cardiovasc. Res. Cable 35 553 1997 10.1016/S0008-6363(97)00161-2 Expression and function of a recombinant endothelial nitric oxide synthase gene in porcine coronary arteries 

  196. Circulation Cable 96 II-173 1997 Recombinant endothelial nitric oxide synthase-transduced human saphenous veins. Gene therapy to augment nitric oxide production in bypass conduits 

  197. J. Am. Coll. Surg. Shears 187 295 1998 10.1016/S1072-7515(98)00163-X Efficient inhibition of intimal hyperplasia by adenovirus-mediated inducible nitric oxide synthase gene transfer to rats and pigs in vivo 

  198. Proc. Nat. Acad. Sci. USA Von Der Leyen 92 1137 1995 10.1073/pnas.92.4.1137 Gene therapy inhibiting neointimal vascular lesion 

  199. Circulation Janssens 97 1274 1998 10.1161/01.CIR.97.13.1274 Human endothelial nitric oxide synthase gene transfer inhibits vascular smooth muscle cell proliferation and neointima formation after balloon injury in rats 

  200. Circulation Varenne 98 919 1998 10.1161/01.CIR.98.9.919 Local adenovirus-mediated transfer of human endothelial nitric oxide synthase reduces luminal narrowing after coronary angioplasty in pigs 

  201. J. Clin. Invest. Newman 96 2955 1995 10.1172/JCI118367 Adenovirus-mediated gene transfer into normal rabbit arteries results in prolonged vascular cell activation, inflammation, and neointimal hyperplasia 

  202. Circulation Zhou 100 1569 1999 10.1161/01.CIR.100.14.1569 Cytomegalovirus infection of rats increases the neointimal response to vascular injury without consistent evidence of direct infection of the vascular wall 

  203. Circ. Res. Chen 82 862 1998 10.1161/01.RES.82.8.862 Overexpression of human endothelial nitric oxide synthase in rat vascular smooth muscle cells and in balloon-injured carotid artery 

  204. Circ. Res. Baek 82 295 1998 10.1161/01.RES.82.3.295 Gene therapy for restenosis. Getting nearer the heart of the matter 

  205. Circ. Res. De Young 82 306 1998 10.1161/01.RES.82.3.306 Gene therapy for restenosis. Are we ready? 

  206. Circ. Res. Libby 82 404 1998 10.1161/01.RES.82.3.404 Gene therapy of restenosis. Promise and perils 

  207. Science Rosenberg 287 1751 2000 10.1126/science.287.5459.1751 Gene therapist, heal thyself 

  208. Circulation Rosengart 100 468 1999 10.1161/01.CIR.100.5.468 Angiogenesis gene therapy. Phase I assessment of direct intramyocardial administration of an adenovirus vector expressing VEGF121 cDNA to individuals with clinically significant severe coronary artery disease 

  209. Naun-Schmied. Arch. Pharmacol. Feelisch 358 113 1998 10.1007/PL00005231 The use of nitric oxide donors in pharmacological studies 

  210. J. Am. Coll. Cardiol. Anderson 24 555 1994 10.1016/0735-1097(94)90316-6 Nitric oxide and nitrovasodilators 

  211. Circ. Res. Mohazzab-H 84 220 1999 10.1161/01.RES.84.2.220 Potential role of a membrane-bound NADH oxidoreductase in nitric oxide release and arterial relaxation to nitroprusside 

  212. Circulation Weidinger 84 755 1991 10.1161/01.CIR.84.2.755 Hypercholesterolemia enhances macrophage recruitment and dysfunction of regenerated endothelium after balloon injury of the rabbit iliac artery 

  213. Atherosclerosis Kariya 80 143 1989 10.1016/0021-9150(89)90022-1 Antiproliferative action of cyclic GMP-elevating vasodilators in cultured rabbit aortic smooth muscle cells 

  214. J. Vasc. Surg. Wolf 21 499 1995 10.1016/S0741-5214(95)70293-8 Nitroglycerine decreases medial smooth muscle cell proliferation after arterial balloon injury 

  215. Atherosclerosis Seki 117 97 1995 10.1016/0021-9150(95)05563-C FK409, a new nitric-oxide donor, suppressed smooth muscle proliferation in the rat model of balloon angioplasty 

  216. Meth. Enzymol. Keefer 268 281 1996 10.1016/S0076-6879(96)68030-6 “NONOates” (1-substituted diazen-1-ium-1,2-diolates) as nitric oxide donors 

  217. Clin. Exp. Pharmacol. Physiol. Yin 24 436 1997 10.1111/j.1440-1681.1997.tb01218.x A nitric oxide donor (spermine-NONOATE) prevents the formation of neointima in rabbit carotid artery 

  218. J. Am. Coll. Cardiol. Kaul 35 493 2000 10.1016/S0735-1097(99)00543-4 Polymeric-based perivascular delivery of a nitric oxide donor inhibits intimal thickening after balloon denudation arterial injury 

  219. Coron. Artery Dis. Buergler 11 351 2000 10.1097/00019501-200006000-00009 Use of nitric-oxide-eluting polymer-coated coronary stents for prevention of restenosis in pigs 

  220. Am. J. Physiol. Siegfried 263 H771 1992 Beneficial effects of SPM-5185, a cysteine-containing NO donor, in myocardial ischemia-reperfusion 

  221. J. Cardiovasc. Pharmacol. De Meyer 26 272 1995 10.1097/00005344-199508000-00013 Effect of nitric oxide donors on neointima formation and vascular reactivity in the collared carotid artery of rabbits 

  222. Am. J. Physiol. Guo 269 H1122 1995 Mechanisms of vascular preservation by a novel NO donor following rat carotid artery intimal injury 

  223. Free Radic. Biol. Med. Jourd’Heuil 28 409 2000 10.1016/S0891-5849(99)00257-9 Dynamic state of S-nitrosothiols in human plasma and whole blood 

  224. J. Clin. Invest. Marks 96 2630 1995 10.1172/JCI118328 Inhibition of neointimal proliferation in rabbits after vascular injury by a single treatment with a protein adduct of nitric oxide 

  225. J. Am. Coll. Cardiol. Maalej 33 1408 1999 10.1016/S0735-1097(98)00687-1 The potent platelet inhibitory effects of S-nitrosated albumin coating of artificial surfaces 

  226. Lancet Langford 344 1458 1994 10.1016/S0140-6736(94)90287-9 Inhibition of platelet activity by S-nitrosoglutathione during coronary angioplasty 

  227. J. Cardiovasc. Pharmacol. Feelisch 14 S13 1989 10.1097/00005344-198914110-00004 On the mechanism of NO release from sydnonimines 

  228. Cardiovasc. Res. Groves 30 87 1995 10.1016/0008-6363(95)00009-7 The effects of exogenous nitric oxide on smooth muscle cell proliferation following porcine carotid angioplasty 

  229. Circulation LaBlanche 95 83 1997 10.1161/01.CIR.95.1.83 Effect of the direct nitric oxide donors linsidomine and molsidomine on angiographic restenosis after coronary balloon angioplasty. The ACCORD study 

  230. J. Cardiovasc. Pharmacol. Thaulow 33 S12 1999 10.1097/00005344-199900002-00004 Pharmacologic effects of calcium channel blockers on restenosis 

  231. Am. J. Physiol. Davidson 17 L437 1997 NO elicits prolonged relaxation of bovine pulmonary arteries via endogenous peroxynitrite generation 

  232. Nature Ernst 385 480 1997 10.1038/385480c0 Alternative therapy bias 

  233. Circulation Bilder 99 3292 1999 10.1161/01.CIR.99.25.3292 Restenosis following angioplasty in the swine coronary artery is inhibited by an orally active PDGF-receptor tyrosine kinase inhibitor, RPR10511A 

  234. Antisense Nucleic Acid Drug Dev. Lee 9 487 1999 10.1089/oli.1.1999.9.487 Antisense strategies to inhibit restenosis 

  235. Grube, E.; Gerkens, U.; Oesterle, S.; Pomerantsev, E.; Pomerantseva, I.; Froix, M.; Eury, R.; Yeung, A.; Stertzer, S. Inhibition of in-stent restenosis by the Quanam drug delivery polymer stent, in humans followed for up to eight months. J. Am. Coll. Cardiol. 35:A34 (abstr.); 2000. 

  236. Circ. Res. Sun 85 288 1999 10.1161/01.RES.85.3.288 Enhanced release of prostaglandins contributes to flow-induced arteriolar dilation in eNOS knockout mice 

  237. Hum. Gene Ther. Laitinen 8 1737 1997 10.1089/hum.1997.8.15-1737 VEGF gene transfer reduces intimal thickening via increased production of nitric oxide in carotid arteries 

  238. Nat. Med. Tsurmi 3 879 1997 10.1038/nm0897-879 Reciprocal relation between VEGF and NO in the regulation of endothelial integrity 

  239. Am. J. Physiol. Sharma 276 H1450 1999 NOS gene transfer inhibits expression of cell cycle regulatory molecules in vascular smooth muscle cells 

  240. Gastroenterology Fiorucci 118 404 2000 10.1016/S0016-5085(00)70223-X NO-aspirin protects from T cell-mediated liver injury by inhibiting caspase-dependent processing of Th1-like cytokines 

  241. Circulation Tanner 101 1982 2000 10.1161/01.CIR.101.16.1982 Nitric oxide modulates expression of cell cycle regulatory proteins. Cytostatic strategy for inhibition of human vascular smooth muscle cell proliferation 

  242. Clin. Exp. Pharmacol. Physiol. Lee 26 1013 1999 10.1046/j.1440-1681.1999.03183.x Role of inducible nitric oxide synthase in transplant atherosclerosis 

  243. Circulation Dorros 98 642 1998 10.1161/01.CIR.98.7.642 Four year follow-up of Palmaz-Schatz stent revascularization as treatment for atherosclerotic renal artery stenosis 

  244. 10.1161/01.CIR.100.3.236 Buller, C. T.; Dzavik, V.; Carere, R. G.; Mancini, J.; Barbeau, G.; Lazzam, C.; Anderson, T. J.; Knudtson, M. L.; Marquis, J.-F.; Suzuki, T.; Cohen, E. A.; Fox, R. S.; Teo, K. K., for the TOSCA investigators. Stenting versus balloon angioplasty in occluded coronary arteries. The total occlusion study of Canada (TOSCA). Circulation 100:236-242; 1999. 

  245. Int. J. Exp. Pathol. Ferns 81 63 2000 10.1046/j.1365-2613.2000.00143.x The mechanisms of coronary restenosis 

  246. J. Vasc. Interv. Radiol. Narayanaswamy 11 5 2000 10.1016/S1051-0443(07)61271-8 Animal models for atherosclerosis, restenosis, and endovascular graft research 

  247. Cardiovasc. Res. Pasterkamp 45 843 2000 10.1016/S0008-6363(99)00377-6 Arterial remodeling in atherosclerosis, restenosis and after alteration of blood flow 

  248. Circulation Ward 102 1186 2000 10.1161/01.CIR.102.10.1186 Arterial remodeling. Mechanisms and clinical implications 

  249. Front. Biosci. Petkova 5 D452 2000 10.2741/Petkova Cell cycle molecules and diseases of the cardiovascular system 

  250. Histol. Histopathol. Rivard 15 557 2000 Vascular smooth muscle cell proliferation in the pathogenesis of atherosclerotic cardiovascular diseases 

  251. Trends Pharmacol. Sci. Bult 21 274 2000 10.1016/S0165-6147(00)01505-4 Restenosis 

  252. Circulation Kuntz 101 2130 2000 10.1161/01.CIR.101.18.2130 Prevention of coronary restenosis 

  253. Circulation Raizner 102 951 2000 10.1161/01.CIR.102.9.951 Inhibition of restenosis with β-emitting radiotherapy. Report of the proliferation reduction with vascular energy trial (PREVENT) 

  254. Circulation Thorin 101 1430 2000 10.1161/01.CIR.101.12.1430 Influence of postangioplasty beta-irradiation on endothelial function in porcine coronary arteries 

  255. Circulation Loscalzo 101 2126 2000 10.1161/01.CIR.101.18.2126 What we know and don’t know about L-arginine and NO 

  256. Scand. Cardiovasc. J. Holm 34 28 2000 10.1080/14017430050142369 Effects of L-arginine on vascular smooth muscle cell proliferation and apoptosis after balloon injury 

  257. Hypertension Garg 36 430 2000 10.1161/01.HYP.36.3.430 Troglitazone reduces reactive oxygen species generation by leukocytes and lipid peroxidation and improves flow-mediated vasodilation in obese subjects 

  258. Circulation Virdis 101 2258 2000 10.1161/01.CIR.101.19.2258 Mechanisms responsible for endothelial dysfunction associated with acute estrogen deprivation in normotensive women 

  259. Circulation Stefano 101 1594 2000 10.1161/01.CIR.101.13.1594 Cell-surface estrogen receptors mediate calcium-dependent nitric oxide release in human endothelia 

  260. Hypertension Agata 36 364 2000 10.1161/01.HYP.36.3.364 Bradykinin B1 receptor mediates inhibition of neointima formation in rat artery after balloon angioplasty 

관련 콘텐츠

저작권 관리 안내
섹션별 컨텐츠 바로가기

AI-Helper ※ AI-Helper는 오픈소스 모델을 사용합니다.

AI-Helper 아이콘
AI-Helper
안녕하세요, AI-Helper입니다. 좌측 "선택된 텍스트"에서 텍스트를 선택하여 요약, 번역, 용어설명을 실행하세요.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.

선택된 텍스트

맨위로